Ghodrat Montazeri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ghodrat Montazeri has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Reza Malekzadeh
Tehran University of Medical Sciences
4 shared publications Arezoo Estakhri
Univ Tehran Med Sci, Digest Dis Res Ctr, Tehran, Iran
2 shared publications- Ashraf Mohamadkhani
Digestive Disease Research Centre, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran
2 shared publications - Farhad Montazeri
Digestive Disease Research Center, Shariati Hospital, Medical sciences/Tehran University, 72, Karegar Shomali Avenue, 17th street, 1438837431, Tehran, Iran
2 shared publications - Farhad Zamani
Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran
2 shared publications - Mehdi Mohamadnejad
Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- 1 May 2010
- Vol. 13 (3) , 193-202
Liver Histology and HBV DNA Levels in Chronically HBV Infected Patients with Persistently Normal Alanine Aminotransferase
Background: Data on histological activity and HBV DNA levels in patients with chronic HBV infection and persistently normal alanine aminotransferase levels are sparse We aimed to investigate the histological activity and HBV DNA levels in these patients Methods There were 132 patients with HBeAg negative chronic HBV infection and persistently normal alanine aminotransferase levels that were included prospectively Data were dichotomized according to the median levels Associations of histology with HBV DNA and other variables were assessed Results: A total of 80 patients were male The median age was 36 years The median baseline HBV DNA was 2 9Log10 IU/mL There were 50 cases (38%) with a total score >= 5, 53 cases (40 2%) had grade >= 4 and 40 cases (30 3%) had stage >= 2 A baseline HBV DNA = 5, 28 cases (53%) of those with grade >= 4 and 9 cases (22 5%) with stage >= 2 Multivariate analysis of baseline HBV DNA above the median level significantly predicted the total score, grade and stage with an adjusted odds ratio of 5 43, 3 47, and 4 23, respectively when compared to below median values A second liver biopsy was performed in 61 patients The median time interval between the two biopsies was 40 months. Total scores of 23 cases (38%) progressed by >= 2 scores and the HBV DNA of 18 cases (22 5 %) increased by >= 1 Log10 IU when compared to baseline values Conclusions: HBeAg negative chronic HBV infection with persistently normal alanine aminotransferase is not a silent disease Active liver disease may be seen in such patients with viral loads less than 2000 IU/mL
- 1 May 2010
- Vol. 13 (3) , 193-202
Liver Histology and HBV DNA Levels in Chronically HBV Infected Patients with Persistently Normal Alanine Aminotransferase
Background: Data on histological activity and HBV DNA levels in patients with chronic HBV infection and persistently normal alanine aminotransferase levels are sparse We aimed to investigate the histological activity and HBV DNA levels in these patients Methods There were 132 patients with HBeAg negative chronic HBV infection and persistently normal alanine aminotransferase levels that were included prospectively Data were dichotomized according to the median levels Associations of histology with HBV DNA and other variables were assessed Results: A total of 80 patients were male The median age was 36 years The median baseline HBV DNA was 2 9Log10 IU/mL There were 50 cases (38%) with a total score >= 5, 53 cases (40 2%) had grade >= 4 and 40 cases (30 3%) had stage >= 2 A baseline HBV DNA = 5, 28 cases (53%) of those with grade >= 4 and 9 cases (22 5%) with stage >= 2 Multivariate analysis of baseline HBV DNA above the median level significantly predicted the total score, grade and stage with an adjusted odds ratio of 5 43, 3 47, and 4 23, respectively when compared to below median values A second liver biopsy was performed in 61 patients The median time interval between the two biopsies was 40 months. Total scores of 23 cases (38%) progressed by >= 2 scores and the HBV DNA of 18 cases (22 5 %) increased by >= 1 Log10 IU when compared to baseline values Conclusions: HBeAg negative chronic HBV infection with persistently normal alanine aminotransferase is not a silent disease Active liver disease may be seen in such patients with viral loads less than 2000 IU/mL
- Open Access
- 26 November 2009
- Published by Springer Nature in Virology Journal
- Vol. 6 (1) , 209
The role of mutations in core protein of hepatitis B virus in liver fibrosis
The core protein of hepatitis B virus encompasses B- and T-cell immunodominant epitopes and subdivided into two domains: the N-terminal and the functional C-terminal consisted phosphorylation sites. Mutations of the core gene may change the conformation of the core protein or cause alteration of important epitopes in the host immune response. In this study twenty nine men (mean age 40 +/- 9 years old) with chronic hepatitis B were recruited for direct sequencing of the core gene. Serum ALT and HBV DNA level were measured at the time of liver biopsy. The effects of core protein mutations on patients' characteristics and subsequently mutations in B cell, T helper and cytotoxic T lymphocyte (CTL) epitopes and also C-terminal domain of core protein on the activity of liver disease was evaluated. Liver fibrosis was significantly increased in patients with core protein mutation (1.0 +/- 0.8 vs 1.9 +/- 1.4 for mean stage of fibrosis P = 0.05). Mutations in CTL epitopes and in phosphorylation sites of C-terminal domain of core protein also were associated with higher liver fibrosis (P = 0.003 and P = 0.04; Fisher's exact test for both). Patients with mutation in C-terminal domain had higher serum ALT (62 +/- 17 vs 36 +/- 12 IU/l, p = 0.02). Patients with mutations in B cell and T helper epitopes did not show significant difference in the clinical features. Our data suggests that core protein mutations in CTL epitopes and C-terminal domain accompanied with higher stage of liver fibrosis may be due to alterations in the function of core protein.
- 26 November 2009
- Published by Springer Nature in Virology Journal
- Vol. 6 (1) , 209
Open AccessThe role of mutations in core protein of hepatitis B virus in liver fibrosis
The core protein of hepatitis B virus encompasses B- and T-cell immunodominant epitopes and subdivided into two domains: the N-terminal and the functional C-terminal consisted phosphorylation sites. Mutations of the core gene may change the conformation of the core protein or cause alteration of important epitopes in the host immune response. In this study twenty nine men (mean age 40 +/- 9 years old) with chronic hepatitis B were recruited for direct sequencing of the core gene. Serum ALT and HBV DNA level were measured at the time of liver biopsy. The effects of core protein mutations on patients' characteristics and subsequently mutations in B cell, T helper and cytotoxic T lymphocyte (CTL) epitopes and also C-terminal domain of core protein on the activity of liver disease was evaluated. Liver fibrosis was significantly increased in patients with core protein mutation (1.0 +/- 0.8 vs 1.9 +/- 1.4 for mean stage of fibrosis P = 0.05). Mutations in CTL epitopes and in phosphorylation sites of C-terminal domain of core protein also were associated with higher liver fibrosis (P = 0.003 and P = 0.04; Fisher's exact test for both). Patients with mutation in C-terminal domain had higher serum ALT (62 +/- 17 vs 36 +/- 12 IU/l, p = 0.02). Patients with mutations in B cell and T helper epitopes did not show significant difference in the clinical features. Our data suggests that core protein mutations in CTL epitopes and C-terminal domain accompanied with higher stage of liver fibrosis may be due to alterations in the function of core protein.
- 12 June 2008
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 168 (1) , 39-42
Leech endoparasitism: report of a case and review of the literature
We report the case of an 11-year-old boy who presented with fresh blood in his mouth and a history of sore throat during the past 2 weeks that was unresponsive to antibiotic therapy. Inspection of the oral cavity revealed a black circular mass attached to the posterior wall of the oropharynx. This mass was determined to be a live engorged leech. Leech endoparasitism is caused by aquatic leeches that attach themselves to mucus membranes of body cavities after the host has swum in bodies of fresh water or drunk from unsafe water sources. Pharyngeal hirudiniasis may present in different forms depending on the exact location of the parasite in the body and must be included in the list of differential diagnosis for common conditions such as pharyngitis, hemoptysis or anemia in pediatric patients living in endemic areas.
- 12 June 2008
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 168 (1) , 39-42
Leech endoparasitism: report of a case and review of the literature
We report the case of an 11-year-old boy who presented with fresh blood in his mouth and a history of sore throat during the past 2 weeks that was unresponsive to antibiotic therapy. Inspection of the oral cavity revealed a black circular mass attached to the posterior wall of the oropharynx. This mass was determined to be a live engorged leech. Leech endoparasitism is caused by aquatic leeches that attach themselves to mucus membranes of body cavities after the host has swum in bodies of fresh water or drunk from unsafe water sources. Pharyngeal hirudiniasis may present in different forms depending on the exact location of the parasite in the body and must be included in the list of differential diagnosis for common conditions such as pharyngitis, hemoptysis or anemia in pediatric patients living in endemic areas.
- 17 October 2007
- Published by Springer Nature in Annals of Hematology
- Vol. 87 (4) , 333-335
A case of concomitant autosomal recessive osteopetrosis and G6PD deficiency
- 17 October 2007
- Published by Springer Nature in Annals of Hematology
- Vol. 87 (4) , 333-335
A case of concomitant autosomal recessive osteopetrosis and G6PD deficiency
- 1 November 2006
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 18 (11) , 1203-1208
Surface area: a better predictor of disease severity than the height and volume of the barium column in patients with primary achalasia
Subjective assessment of primary achalasia is not accurate. We aimed to study the utility of surface area of barium retention in the objective assessment of these patients. Subjective and objective esophageal functions of 99 patients with primary achalasia were evaluated initially and 43 of them were reevaluated 1 month after balloon dilation. Before dilation: Ninety-nine patients were enrolled. Forty-one of them were male. The mean age was 37.5+/-15.3 years. The mean score, resting lower esophageal sphincter pressure, height, surface and volume of barium retention at 5 min were 8.03+/-3.1, 59.1+/-20 mmHg, 9.9+/-4.9 cm, and 23.6+/-13.9 cm and 53.2+/-47.7 cm, respectively. Surface area at 5 min had best correlation and predictive value for resting lower esophageal sphincter pressure. After dilation: Forty-three of 99 patients were reevaluated after balloon dilation. The mean age was 36.8+/-13.6 years. Seventeen of them were male. Mean score, resting lower esophageal sphincter pressure, height, surface area and volume of barium retention at 5 min dropped significantly after dilation. Surface area at 5 min had best correlation and predictive value for lower esophageal sphincter pressure. Surface area of barium retention at 5 min is an accurate objective tool to assess patients with primary achalasia. It is cheap and easy to perform; therefore, it could be used more frequently in postdilation follow-up.
- 1 November 2006
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 18 (11) , 1203-1208
Surface area: a better predictor of disease severity than the height and volume of the barium column in patients with primary achalasia
Subjective assessment of primary achalasia is not accurate. We aimed to study the utility of surface area of barium retention in the objective assessment of these patients. Subjective and objective esophageal functions of 99 patients with primary achalasia were evaluated initially and 43 of them were reevaluated 1 month after balloon dilation. Before dilation: Ninety-nine patients were enrolled. Forty-one of them were male. The mean age was 37.5+/-15.3 years. The mean score, resting lower esophageal sphincter pressure, height, surface and volume of barium retention at 5 min were 8.03+/-3.1, 59.1+/-20 mmHg, 9.9+/-4.9 cm, and 23.6+/-13.9 cm and 53.2+/-47.7 cm, respectively. Surface area at 5 min had best correlation and predictive value for resting lower esophageal sphincter pressure. After dilation: Forty-three of 99 patients were reevaluated after balloon dilation. The mean age was 36.8+/-13.6 years. Seventeen of them were male. Mean score, resting lower esophageal sphincter pressure, height, surface area and volume of barium retention at 5 min dropped significantly after dilation. Surface area at 5 min had best correlation and predictive value for lower esophageal sphincter pressure. Surface area of barium retention at 5 min is an accurate objective tool to assess patients with primary achalasia. It is cheap and easy to perform; therefore, it could be used more frequently in postdilation follow-up.
- 1 January 2006
- Vol. 9 (1) , 1-10
Current treatment of chronic hepatitis B.
The primary goal of therapy in patients with chronic hepatitis B is suppression and long-lasting maintenance of hepatitis B virus DNA to its lowest possible level. The threshold of hepatitis B virus DNA level for therapy is > or = 10(5) copies/mL for HBeAg-positive patients and > or = 10(4) for those with HBeAg-negative chronic hepatitis B. Interferon alpha-2b, lamivudine, and adefovir-dipivoxil are approved by FDA and could all be used as an initial first-line therapy in chronic hepatitis B. Adding lamivudine to either conventional interferon or peg-interferon did not increase the efficacy. Adding lamivudine to adefovir had also no additional effect in compensated patients. Response rate is about 30% - 40% with first-line drugs. Peg-interferon, which recently received the FDA approval, is associated with an increased response rate. Further long-term studies are required to use peg-interferon as a widespread first-line treatment. Treatment strategy is changing towards using prolonged combination therapy with evolving nucleoside analogues with or without an immunomodulatory agent, aiming at eradicating covalently closed circular DNA.
- 1 January 2006
- Vol. 9 (1) , 1-10
Current treatment of chronic hepatitis B.
The primary goal of therapy in patients with chronic hepatitis B is suppression and long-lasting maintenance of hepatitis B virus DNA to its lowest possible level. The threshold of hepatitis B virus DNA level for therapy is > or = 10(5) copies/mL for HBeAg-positive patients and > or = 10(4) for those with HBeAg-negative chronic hepatitis B. Interferon alpha-2b, lamivudine, and adefovir-dipivoxil are approved by FDA and could all be used as an initial first-line therapy in chronic hepatitis B. Adding lamivudine to either conventional interferon or peg-interferon did not increase the efficacy. Adding lamivudine to adefovir had also no additional effect in compensated patients. Response rate is about 30% - 40% with first-line drugs. Peg-interferon, which recently received the FDA approval, is associated with an increased response rate. Further long-term studies are required to use peg-interferon as a widespread first-line treatment. Treatment strategy is changing towards using prolonged combination therapy with evolving nucleoside analogues with or without an immunomodulatory agent, aiming at eradicating covalently closed circular DNA.
- Open Access
- 12 October 2005
- Published by Springer Nature in BMC Gastroenterology
- Vol. 5 (1) , 32
Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B
Background: HBV infection is a serious global heath problem. It is crucial to monitor this disease more closely with a non-invasive marker in clinical trials. We aimed to evaluate the predictive value of serum hyaluronate for the presence of extensive liver fibrosis and inflammation. Methods: 28 healthy volunteers and 65 patients with HBeAg negative chronic hepatitis B were enrolled. Liver biopsies scored according to Ishak system. Association of serum hyaloronate with liver fibrosis and inflammation were assessed, and cut off points for serum hyaluronate levels were identified by receiver operating characteristics (ROC) curves and their values for prediction of fibrosis and inflammation were assessed. Results: In patients with CHB serum hyaluronate had the most significant correlation and predictive values for the liver fibrosis and inflammation comparing to the other variables. At the cut off point of 126.4 ngm/ml it could discriminate extensive fibrosis from milder ones with sensitivity of 90.9% and specificity of 98.1%. With the same value it could discriminate extensive inflammation from their milder counterparts with sensitivity of 63.6% and specificity of 92.6%. Conclusion: Serum hyaluronate was the best predictor of extensive liver fibrosis and inflammation and it could discriminate subgroups of patients with chronic hepatitis B. It could be used as a non-invasive test to monitor these patients more closely with developing anti viral agents in clinical trials.
- 12 October 2005
- Published by Springer Nature in BMC Gastroenterology
- Vol. 5 (1) , 32
Open AccessSerum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B
Background: HBV infection is a serious global heath problem. It is crucial to monitor this disease more closely with a non-invasive marker in clinical trials. We aimed to evaluate the predictive value of serum hyaluronate for the presence of extensive liver fibrosis and inflammation. Methods: 28 healthy volunteers and 65 patients with HBeAg negative chronic hepatitis B were enrolled. Liver biopsies scored according to Ishak system. Association of serum hyaloronate with liver fibrosis and inflammation were assessed, and cut off points for serum hyaluronate levels were identified by receiver operating characteristics (ROC) curves and their values for prediction of fibrosis and inflammation were assessed. Results: In patients with CHB serum hyaluronate had the most significant correlation and predictive values for the liver fibrosis and inflammation comparing to the other variables. At the cut off point of 126.4 ngm/ml it could discriminate extensive fibrosis from milder ones with sensitivity of 90.9% and specificity of 98.1%. With the same value it could discriminate extensive inflammation from their milder counterparts with sensitivity of 63.6% and specificity of 92.6%. Conclusion: Serum hyaluronate was the best predictor of extensive liver fibrosis and inflammation and it could discriminate subgroups of patients with chronic hepatitis B. It could be used as a non-invasive test to monitor these patients more closely with developing anti viral agents in clinical trials.
- 1 August 2005
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 22 (3) , 261-265
Lower oesophageal sphincter pressure and timed barium oesophagogram: two objective parameters in the non-invasive assessment of primary achalasia
The non-invasive assessment of primary achalasia is not precise. To compare investigations before and 1 month after balloon dilation in achalasia. Fifty-two patients with primary achalasia were enrolled. Subjective and objective variables of oesophageal functions were analysed before and 1 month after balloon dilation. The mean predilation symptom score, lower oesophageal sphincter pressure, height and volume of barium at 5 min were 7.7 +/- 2.6, 62.0 +/- 25.1 mmHg, 9.2 +/- 6.1 cm and 53.2 +/- 49.8 mL respectively; the mean postdilation values were 3.0 +/- 3.0, 34.1 +/- 12.5 mmHg, 7.9 +/- 5.1 cm and 28.0 +/- 30.1 mL respectively. The before dilation volume of barium at 5 min correlates significantly with lower oesophageal sphincter pressure (P < 0.01). The mean symptom scores, lower oesophageal sphincter pressure and volume of barium at 5 min dropped significantly after intervention (P < 0.01), but the reduction in barium height at 5 min was not significant. The percentage changes in volume at 5 min significantly predicted the percentage changes in lower oesophageal sphincter pressure (P < 0.01). The volume of barium retention at 5 min can predict the lower oesophageal sphincter pressure before and after balloon dilation in primary achalasia. This could be used as a non-invasive objective tool for initial and post-dilation assessment.
- 1 August 2005
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 22 (3) , 261-265
Lower oesophageal sphincter pressure and timed barium oesophagogram: two objective parameters in the non-invasive assessment of primary achalasia
The non-invasive assessment of primary achalasia is not precise. To compare investigations before and 1 month after balloon dilation in achalasia. Fifty-two patients with primary achalasia were enrolled. Subjective and objective variables of oesophageal functions were analysed before and 1 month after balloon dilation. The mean predilation symptom score, lower oesophageal sphincter pressure, height and volume of barium at 5 min were 7.7 +/- 2.6, 62.0 +/- 25.1 mmHg, 9.2 +/- 6.1 cm and 53.2 +/- 49.8 mL respectively; the mean postdilation values were 3.0 +/- 3.0, 34.1 +/- 12.5 mmHg, 7.9 +/- 5.1 cm and 28.0 +/- 30.1 mL respectively. The before dilation volume of barium at 5 min correlates significantly with lower oesophageal sphincter pressure (P < 0.01). The mean symptom scores, lower oesophageal sphincter pressure and volume of barium at 5 min dropped significantly after intervention (P < 0.01), but the reduction in barium height at 5 min was not significant. The percentage changes in volume at 5 min significantly predicted the percentage changes in lower oesophageal sphincter pressure (P < 0.01). The volume of barium retention at 5 min can predict the lower oesophageal sphincter pressure before and after balloon dilation in primary achalasia. This could be used as a non-invasive objective tool for initial and post-dilation assessment.